Bringing Evidence into Practice : Psoriasis Management in the Age of Newer Biologics
WebcastFaculty
OVERVIEW
Bringing Evidence into Practice : Psoriasis Management in the Age of Newer Biologics is organized by UK HealthCare CECentral and will be held during Apr 20, 2017 - Apr 21, 2018.
The target audience for this medical event is physicians specializing in dermatology. It will also benefit dermatology nurse practitioners, and PAs, as well as primary care clinicians (internal medicine and family practice) who manage patients with psoriasis.This CME Conference has been approved for a maximum of 1.25 AMA PRA Category 1 Credits.
The dermatologist is the primary provider for patients with plaque psoriasis. Many primary care practitioners (PCPs) also manage patients with psoriasis, although at a much lower frequency.
Conference Objectives :
Upon completion of this educational activity, participants will be able to:
• Review the clinical guideline recommendations for earlier, aggressive treatment of moderate to severe plaque psoriasis as a systemic disease with systemic agents and/or biologic drugs.
• Explain newer pathways for the development of plaque psoriasis and their implications for determining treatment, based on current evidence.
• Summarize the most current evidence for newer therapies, which will guide patient selection, treatment goals, and response monitoring in patients with psoriasis.
Additional details will be posted as soon as they are available.
The target audience for this medical event is physicians specializing in dermatology. It will also benefit dermatology nurse practitioners, and PAs, as well as primary care clinicians (internal medicine and family practice) who manage patients with psoriasis.This CME Conference has been approved for a maximum of 1.25 AMA PRA Category 1 Credits.
The dermatologist is the primary provider for patients with plaque psoriasis. Many primary care practitioners (PCPs) also manage patients with psoriasis, although at a much lower frequency.
Conference Objectives :
Upon completion of this educational activity, participants will be able to:
• Review the clinical guideline recommendations for earlier, aggressive treatment of moderate to severe plaque psoriasis as a systemic disease with systemic agents and/or biologic drugs.
• Explain newer pathways for the development of plaque psoriasis and their implications for determining treatment, based on current evidence.
• Summarize the most current evidence for newer therapies, which will guide patient selection, treatment goals, and response monitoring in patients with psoriasis.
Additional details will be posted as soon as they are available.
SPECIALITIES
DermatologyRELATED ONLINE COURSES
Quick Links